- Home
- AERT vs IGC Comparison
AERT vs IGC Comparison
Compare AERT & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AERT
- IGC
- Stock Information
- Founded
- AERT 2012
- IGC 2005
- Country
- AERT Singapore
- IGC United States
- Employees
- AERT N/A
- IGC N/A
- Industry
- AERT Professional Services
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- AERT Consumer Discretionary
- IGC Health Care
- Exchange
- AERT Nasdaq
- IGC Nasdaq
- Market Cap
- AERT 37.6M
- IGC 31.0M
- IPO Year
- AERT N/A
- IGC N/A
- Fundamental
- Price
- AERT $0.88
- IGC $0.37
- Analyst Decision
- AERT
- IGC Strong Buy
- Analyst Count
- AERT 0
- IGC 2
- Target Price
- AERT N/A
- IGC $3.88
- AVG Volume (30 Days)
- AERT 7.0M
- IGC 732.2K
- Earning Date
- AERT 08-14-2025
- IGC 08-14-2025
- Dividend Yield
- AERT N/A
- IGC N/A
- EPS Growth
- AERT N/A
- IGC N/A
- EPS
- AERT N/A
- IGC N/A
- Revenue
- AERT $68,861,000.00
- IGC $1,327,000.00
- Revenue This Year
- AERT N/A
- IGC $15.26
- Revenue Next Year
- AERT N/A
- IGC $3.41
- P/E Ratio
- AERT N/A
- IGC N/A
- Revenue Growth
- AERT N/A
- IGC 24.95
- 52 Week Low
- AERT $0.46
- IGC $0.25
- 52 Week High
- AERT $2.80
- IGC $0.48
- Technical
- Relative Strength Index (RSI)
- AERT 48.96
- IGC 56.73
- Support Level
- AERT $0.73
- IGC $0.35
- Resistance Level
- AERT $1.15
- IGC $0.37
- Average True Range (ATR)
- AERT 0.14
- IGC 0.02
- MACD
- AERT 0.01
- IGC 0.00
- Stochastic Oscillator
- AERT 30.09
- IGC 69.17
About AERT Aeries Technology Inc.
Aeries Technology Inc is a professional and management services partner offering a range of management consultancy services for private equity sponsors and their portfolio companies with engagement models that are designed to provide a mix of deep vertical specialty, functional expertise, and digital systems and solutions to scale, optimize and transform a client's business operations. It supports and drives its client's growth across the globe by providing a range of management consultancy services involving professional advisory services and operations management services to build and manage dedicated delivery centers in appropriate locations based on customer business needs.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.